Does Blue Cross Blue Shield of Illinois Cover Lantus?

What Is Lantus and Why Does Coverage Matter for Illinois Patients?

Lantus is a long-acting basal insulin that delivers 24-hour glucose control with a single daily injection. For the roughly 1.1 million Illinois adults living with diagnosed diabetes, according to CDC surveillance data, access to affordable basal insulin can be the difference between consistent glycemic control and dangerous gaps in therapy.

The Drug Itself

Lantus contains insulin glargine at 100 units/mL. The FDA first approved it in April 2000, and it remains one of the most prescribed basal insulins in the United States. FDA labeling for Lantus documents its indication for both type 1 and type 2 diabetes in adults and pediatric patients aged 6 and older.

Why Formulary Tier Matters

Insurance formularies divide drugs into cost tiers. Tier 1 drugs are the cheapest, usually generics. Tier 3 or Tier 4 drugs carry higher cost-sharing. Because Lantus is a brand-name biologic, it typically lands on Tier 3 or Tier 4 on BCBS Illinois commercial plans, which translates to higher out-of-pocket costs than biosimilar insulin glargine products placed on Tier 2.

The American Diabetes Association's 2024 Standards of Care states that "insulin therapy is recommended for patients with type 2 diabetes who do not achieve or maintain glycemic goals with noninsulin therapies." That clinical imperative makes coverage access a direct patient safety issue.

How BCBS Illinois Formularies Are Structured

BCBS Illinois operates several distinct plan families, and each has its own formulary document. Knowing which plan you hold is the starting point for any coverage question.

Commercial PPO and HMO Plans

Blue Cross Blue Shield of Illinois commercial PPO plans (including Blue Advantage, Blue Choice, and BlueEdge) follow a 5-tier formulary in most years. Lantus typically appears on Tier 3 or Tier 4. A 2023 JAMA Internal Medicine analysis found that insulin cost-sharing under commercial insurance varies widely, with patients paying anywhere from $0 to more than $300 per month depending on deductible status and plan tier.

Medicare Advantage Plans

BCBS Illinois Medicare Advantage (Blue Cross Medicare Advantage) follows Medicare Part D formulary rules. The Inflation Reduction Act of 2022 capped insulin copays at $35 per month for Medicare Part D beneficiaries starting January 1, 2023. CMS confirmed this cap applies to covered insulins including Lantus when dispensed through a network pharmacy.

Illinois State Employee Plans

The State Employees Group Insurance Program (SEGIP) administered through BCBS Illinois follows Illinois Department of Central Management Services formulary rules. Lantus coverage under SEGIP may differ from commercial formulary placement.

Medicaid Managed Care

BCBS Illinois also administers Medicaid managed care plans in Illinois. Illinois Medicaid covers insulin broadly, and cost-sharing for Medicaid beneficiaries is governed by 42 CFR Part 447, which limits cost-sharing for categorically needy enrollees.

Does BCBS Illinois Require Prior Authorization for Lantus?

Prior authorization (PA) is required on many, though not all, BCBS Illinois plans for Lantus. The specific trigger conditions vary, but several common PA criteria appear across BCBS Illinois commercial plans.

Common PA Criteria

BCBS Illinois prior authorization for Lantus typically requires confirmation that the patient has a diagnosis of type 1 or type 2 diabetes mellitus supported by clinical documentation. Some plans require evidence that the prescriber tried at least one biosimilar insulin glargine product first, or a clinical reason why the biosimilar is not appropriate. Quantity limits (such as 10 mL vials per 30-day supply) may trigger additional review.

The FDA's Biosimilar Action Plan notes that biosimilar insulins such as Basaglar (insulin glargine-yfgn) and Semglee (insulin glargine-yfgn) are interchangeable with Lantus at the pharmacy level in states that permit therapeutic substitution. Illinois law allows pharmacists to substitute interchangeable biosimilars unless the prescriber writes "dispense as written."

How Long PA Approval Takes

Most BCBS Illinois commercial plan PA requests for insulin receive a decision within 1 to 3 business days for standard review. Urgent requests (defined as cases where a standard timeframe would seriously jeopardize health) must receive a decision within 72 hours under Illinois insurance law, per 215 ILCS 5/155.04.

What Happens If PA Is Denied

A PA denial is not a final answer. BCBS Illinois members have the right to appeal. First-level internal appeals must be filed within 180 days of the denial notice. If the internal appeal fails, Illinois law permits an external independent review through the Illinois Department of Insurance.

What Does Lantus Cost Under BCBS Illinois?

Out-of-pocket cost depends on four variables: your specific plan, your deductible status, your pharmacy (retail vs. Mail-order vs. Specialty), and whether a copay assistance program applies.

Retail Pharmacy Costs

On a typical BCBS Illinois commercial PPO, Lantus (one 10 mL vial, 1,000 units) may cost:

• Before deductible is met: full negotiated rate, often $150, $280 per vial
• After deductible, Tier 3 copay: approximately $50, $99 per 30-day supply
• After deductible, Tier 4 copay: approximately $75, $150 per 30-day supply

These figures reflect plan year 2024 benefit designs. Always verify with the BCBS Illinois drug cost tool or call 1-800-835-8699.

Mail-Order Pharmacy Savings

BCBS Illinois typically offers a 90-day supply through its mail-order benefit (Prime Therapeutics is the pharmacy benefit manager for BCBS Illinois commercial plans). The 90-day mail-order copay is often 2 times the 30-day copay rather than 3 times, producing a meaningful per-unit savings.

The Illinois $100/Month Insulin Cap

Illinois Senate Bill 667, signed into law in 2021, capped insulin cost-sharing at $100 per 30-day supply for state-regulated health insurance plans. This cap applies to BCBS Illinois fully-insured commercial plans. Self-insured employer plans (governed by federal ERISA law) are not required to follow the state cap. Illinois Department of Insurance guidance outlines which plans qualify.

Sanofi Valyou Patient Assistance

Sanofi, Lantus's manufacturer, offers the Valyou Savings Program, which can reduce Lantus cost to as low as $99 per month for uninsured or underinsured patients. This is independent of BCBS Illinois coverage.

Biosimilar and Formulary Alternatives to Lantus on BCBS Illinois

If Lantus faces PA hurdles or high cost-sharing, several alternatives may carry better formulary placement.

Interchangeable Biosimilar Insulins

Semglee (insulin glargine-yfgn, Viatris/Biocon) received FDA interchangeable biosimilar designation in July 2021, the first insulin biosimilar to do so. FDA's approval announcement confirmed that pharmacists may substitute Semglee for Lantus without prescriber intervention (unless a "dispense as written" instruction is present).

Basaglar (insulin glargine-yfgn, Eli Lilly) was approved in 2015 and appears on Tier 2 of many BCBS Illinois formularies, potentially saving members $30, $60 per month compared to Lantus.

Rezvoglar (insulin glargine-aglr, Eli Lilly) launched in 2023 at a list price approximately 78% lower than Lantus, according to Eli Lilly's pricing announcement reported by the FDA.

Other Basal Insulin Options

Toujeo (insulin glargine U-300, Sanofi) delivers insulin glargine at 300 units/mL, offering a smaller injection volume for higher-dose patients. A 2019 Lancet Diabetes and Endocrinology meta-analysis found Toujeo produced slightly lower nocturnal hypoglycemia rates versus Lantus U-100 in type 2 diabetes, with comparable HbA1c reductions.

Tresiba (insulin degludec, Novo Nordisk) is another ultra-long-acting basal insulin. The DEVOTE trial (N=7,637) demonstrated that Tresiba reduced severe hypoglycemia by 40% compared to insulin glargine U-100 over 2 years (P<0.001), per results published in NEJM.

How to Check Your Specific BCBS Illinois Plan's Lantus Coverage

Coverage verification takes less than 10 minutes using the right tools.

Step 1: Log In to the BCBS Illinois Member Portal

At bcbsil.com, log in to your account and manage to "Drug Cost and Coverage." Enter "insulin glargine" or "Lantus" in the drug search field. The tool displays your plan's tier, copay, and any PA or step therapy requirements.

Step 2: Call the Pharmacy Benefit Line

Call the number on the back of your BCBS Illinois insurance card and ask the pharmacy benefit representative for:

• The formulary tier for Lantus (NDC 00088-2220-33 for the 10 mL vial)
• Whether prior authorization is required
• The 30-day and 90-day copay amounts after deductible

Step 3: Ask Your Pharmacist to Run a Test Claim

A licensed pharmacist can run a test claim using your BCBS Illinois BIN and PCN numbers to see the exact patient pay amount before you hand over a prescription.

How to Get a PA Approved or Win an Appeal

A prior authorization for insulin is one of the more straightforward PA requests when submitted with the right documentation.

Building a Strong PA Submission

Your prescriber's office should include: a confirmed diabetes diagnosis (ICD-10 code E11.x for type 2, E10.x for type 1), recent HbA1c results, a brief clinical note explaining why Lantus is preferred over biosimilar alternatives (if step therapy applies), and any history of adverse reactions to proposed alternatives.

The ADA's position statement on insulin access emphasizes that "delays in insulin access due to administrative barriers directly harm patient outcomes." That language is worth including in appeal letters.

The External Review Option

If BCBS Illinois denies an internal appeal, Illinois law (215 ILCS 5/155.04) guarantees the right to an Independent Medical Review (IMR) through the Illinois Department of Insurance. IMR decisions are binding on the insurer. Studies of external reviews for prescription drugs show that approximately 39 to 62% of external appeals result in overturn of the denial, making this a genuinely viable route.

Expedited Appeals for Urgent Need

If a patient is out of insulin and a denial has been issued, the appeal may be filed as expedited. BCBS Illinois must respond within 72 hours. Clinicians should document medical urgency explicitly in writing when submitting an expedited appeal.

What ADA and Endocrine Society Guidelines Say About Basal Insulin

Clinical guidelines influence formulary design and PA criteria alike. Understanding what guidelines say helps clinicians and patients argue for coverage on clinical merit.

ADA 2024 Standards of Care

The ADA's 2024 Standards of Care (Section 9) recommends basal insulin as a first-line injectable agent for type 2 diabetes when oral agents and GLP-1 receptor agonists have not achieved glycemic targets. For type 1 diabetes, basal-bolus insulin regimens remain the standard of care. The ADA assigns a Grade A recommendation (highest evidence level) to basal insulin use in type 1 diabetes.

Endocrine Society Guidelines

The Endocrine Society's clinical practice guideline on diabetes management, published in the Journal of Clinical Endocrinology and Metabolism, supports insulin glargine as an appropriate basal insulin option. The guideline notes that insulin glargine U-100 products (including biosimilars) have a well-established safety and efficacy profile across more than two decades of use.

ORIGIN Trial Data

The ORIGIN trial (N=12,537) tested insulin glargine in people with early dysglycemia over a median 6.2 years. Results published in NEJM found that insulin glargine did not increase cardiovascular event rates compared to standard care (hazard ratio 1.02, 95% CI 0.94 to 1.11), providing long-term cardiovascular safety data that supports its use in high-risk patients.

Special Situations: ACA Marketplace, Short-Term Plans, and COBRA

ACA Marketplace Plans Through BCBS Illinois

ACA marketplace plans sold by BCBS Illinois are required to cover prescription drugs as an essential health benefit under 45 CFR 156.122. Insulin is covered on all BCBS Illinois marketplace formularies, but the tier and cost-sharing depend on whether you purchased a Bronze, Silver, Gold, or Platinum plan.

Short-Term Health Plans

Short-term health plans are exempt from ACA essential health benefit rules. BCBS Illinois short-term plans may exclude or strictly limit insulin coverage. Patients on short-term plans should verify Lantus coverage before enrolling.

COBRA Continuation Coverage

COBRA coverage maintains your prior employer plan's formulary. If Lantus was covered on your employer plan, it remains covered under COBRA at the same tier. The cost difference under COBRA is that you pay the full premium rather than the employee share.

Illinois-Specific Patient Assistance and Safety-Net Programs

When insurance coverage falls short, Illinois residents have several additional options.

Illinois Rx Program

The Illinois Department on Aging administers the Circuit Breaker / Illinois Rx Buying Club, which negotiates drug pricing for income-qualifying Illinois residents aged 65 and older or with disabilities.

Sanofi Patient Connection

Sanofi's patient assistance program provides free Lantus to patients with household incomes up to 400% of the federal poverty level who meet eligibility criteria. The program is accessible at Sanofi's patient assistance portal.

Community Health Centers

Federally Qualified Health Centers (FQHCs) in Illinois participate in the 340B Drug Pricing Program, which allows them to purchase Lantus at significantly reduced costs. Patients without adequate insurance coverage may access insulin at substantially lower prices through 340B-participating clinics. HRSA's 340B program information lists participating sites.

Monitoring Glycemic Control Once Coverage Is Secured

Securing Lantus coverage solves only one part of diabetes management. Dose titration and glycemic monitoring determine whether the medication actually works.

Starting Dose and Titration

The FDA-approved starting dose for insulin glargine in type 2 diabetes is typically 0.1 to 0.2 units/kg/day or 10 units once daily, titrated based on fasting blood glucose. ADA guidelines recommend adjusting the dose by 2 units every 3 days until fasting glucose reaches target (typically 80 to 130 mg/dL).

HbA1c Targets

The ADA recommends an HbA1c target of <7.0% for most non-pregnant adults with diabetes. A more relaxed target of <8.0% is appropriate for older adults with limited life expectancy, frequent severe hypoglycemia, or extensive comorbidities. CDC data show that approximately 50% of U.S. Adults with diabetes do not meet their HbA1c target, underscoring the need for both access and adherence support.

Hypoglycemia Risk

A 2021 BMJ meta-analysis of 10 randomized trials found that insulin glargine U-100 carried a lower nocturnal hypoglycemia risk compared to NPH insulin (risk ratio 0.48, 95% CI 0.37 to 0.63, P<0.001), supporting its use as a safer basal option for patients concerned about overnight lows.